Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
165 hedge funds and large institutions have $930M invested in Esperion Therapeutics in 2020 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 36 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
6.44% more ownership
Funds ownership: 101.9% → 108.33% (+6.4%)
4% less funds holding
Funds holding: 172 → 165 (-7)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
31% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $14.2M
43% less capital invested
Capital invested by funds: $1.62B → $930M (-$692M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$69.9M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$40.8M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$27.1M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$17.2M |
| 2 |
Man Group
London,
United Kingdom
|
-$14.6M |
| 3 |
Millennium Management
New York
|
-$9.13M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$9.08M |
| 5 |
Goldman Sachs
New York
|
-$8.91M |
ESPR Hedge Fund Activity: Q1 2020 in Review
165 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2020, worth a combined $930M — down 43% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ESPR and 32 opened new positions — a net loss of 4 holders — while 49 trimmed existing stakes and 57 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $69.9M. The largest seller was Nomura Holdings, cutting an estimated $17.2M.
- 165 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2020, down from 172 in Q4 2019.
- Funds reported $930M of Esperion Therapeutics stock for Q1 2020, down 43% quarter-over-quarter.
- 32 funds opened new Esperion Therapeutics positions in Q1 2020 and 36 closed out, a net change of -4 holders.
- The largest Esperion Therapeutics buyer in Q1 2020 was Marshall Wace, an estimated $69.9M added.
- The largest Esperion Therapeutics seller in Q1 2020 was Nomura Holdings, an estimated $17.2M sold.
Based on aggregated 13F filings for Q1 2020.